24 October 2016
The US Food and Drug Administration (FDA) will today host a scientific workshop on erythropoietic protoporphyria (EPP) at the FDA campus in Silver Spring.
The workshop is open to all EPP stakeholders, with the FDA seeking perspective on EPP disease symptoms, its impact on daily life, experience with current treatment regimens for EPP, and aspects of clinical development of products intended to treat EPP. The meeting will also be available for viewing via webcast for those who have registered, and public online archive thereafter. CLINUVEL’s product SCENESSE® (afamelanotide 16mg) has been evaluated in clinical trials for the prophylactic treatment of EPP.